Homografts and prosthetic valves face formal comparison in infective endocarditis surgery
Surgical teams have long treated infective endocarditis as a race against ongoing tissue destruction. Once infection reaches the native valve or a previously implanted prosthesis, the operative goal shifts from repair in the abstract to removal of infected material, reconstruction of anatomy, and prevention of relapse. In that setting, the choice of replacement material is not a technical detail. It shapes how surgeons think about reinfection risk, durability, and the likelihood that a heavily contaminated field will heal without recurrent sepsis.
The IESCOPO study protocol sets out to test a question that has stayed active in surgical practice for years: whether cryopreserved homografts offer an advantage over conventional prosthetic valves in adults undergoing surgery for active valve infective endocarditis. The protocol frames homografts as a preferred option in expert opinion because of their presumed resistance to infection, yet it also makes plain that comparative evidence has been thin. That gap matters because the belief has often moved ahead of the data.
A three-center cohort built from 20 years of surgical experience
Investigators identified 775 adults, all 18 years or older, who underwent surgery for active infective endocarditis involving the heart valves between 2005 and 2024 across three tertiary academic centers. The long enrollment window gives the study access to a broad real-world surgical experience rather than a narrow snapshot from one high-volume unit. It also introduces the kinds of treatment-selection differences that usually complicate surgical comparisons: sicker patients may have been steered toward one prosthesis type, while patients with different anatomy or operative urgency may have been routed toward another.
To address that problem, the analysis uses propensity score methods and inverse probability of treatment weighting, or IPTW, to balance baseline characteristics between the homograft and conventional prosthetic valve groups. In practical terms, this approach attempts to make the two cohorts look more alike on paper before outcomes are compared, reducing the chance that an apparent difference is driven by case mix rather than by the valve choice itself. For a condition like infective endocarditis, where the sickest patients often arrive with hemodynamic collapse, abscess formation, or extensive valve destruction, that adjustment is essential.
One sentence captures the central challenge: surgical preference alone can distort the truth.
Why the valve material could matter biologically
The biological logic behind the comparison is straightforward. Homografts are implanted as human tissue, and advocates have argued that they may be less hospitable to persistent infection than conventional prosthetic materials. In active infective endocarditis, where infected tissue, biofilm, and friable vegetations can seed the operative field, any material with better resistance to colonization could theoretically lower late reinfection. Conventional prosthetic valves, whether xenograft or mechanical, bring their own strengths and liabilities, including durability or thrombotic considerations, but they do not carry the same historical reputation for infection resistance.
That mechanistic plausibility has helped sustain interest in homografts even in the absence of decisive comparative evidence. Yet valve replacement in infective endocarditis is not governed by microbiology alone. Surgeon experience, lesion extent, annular involvement, periannular abscess, and the ability to debride infected tissue all influence outcomes. The protocol acknowledges this complexity by aiming to minimize biases related to institutional volume and surgical expertise, especially when comparing a technically demanding homograft operation with standard prosthetic implantation.
Short- and long-term outcomes will be judged in a weighted cohort
The study is designed to evaluate both short- and long-term outcomes, although the protocol abstract does not specify the exact endpoint definitions. Even without endpoint detail, the analytic intent is clear: investigators want to determine whether homografts actually translate into measurable benefit after surgery for active valve infective endocarditis, rather than simply carrying a stronger theoretical appeal. By using weighted cohorts with balanced baseline characteristics, the analysis should better isolate the effect of valve choice from the clinical urgency that drove the original operation.
This design is especially relevant because late complications after infective endocarditis surgery can be multifactorial. Recurrent infection, structural valve degeneration, reoperation, and postoperative management challenges may emerge long after the index operation. A prosthesis that performs well in the operating room can still prove problematic if infection recurs, while a more infection-resistant conduit that is technically harder to implant may not necessarily improve the overall course unless that advantage is real and durable.
The protocol also requires participating centers to maintain an infective valve surgery program and to ensure follow-up for late complications. That requirement is more than administrative. It reflects the reality that endocarditis surgery does not end at discharge; the relevant failures may appear months or years later, when relapse, prosthetic dysfunction, or structural degeneration becomes clinically visible.
Guideline pressure will depend on whether the data hold up
If the final analysis shows a meaningful advantage for homografts, the finding could influence how surgeons and guideline writers approach active infective endocarditis, especially in complex valve destruction where infection control is paramount. If no advantage emerges after adjustment, the field may have to reconsider how strongly homografts should be favored over conventional prosthetic valves in routine decision-making. Either result would carry weight, because the current preference for homografts rests on a mixture of biological plausibility, surgical tradition, and incomplete comparative evidence.
The study’s multicenter structure gives it a chance to speak to real-world practice rather than a single expert environment. It also raises the bar for interpretation. If homografts appear superior, the question will become whether the benefit is consistent across centers and operative settings, or whether it depends on the concentration of expertise in a small number of surgeons. If the two approaches look similar after IPTW adjustment, the presumed infection resistance of homografts may prove less decisive than many clinicians have assumed.
Trial registration includes Clinical Trial Gov. Com. ID NCT05253469 and IRB ID 2,022,011,054. The protocol stops short of reporting outcomes, so the field is left with a carefully constructed comparison rather than a clinical verdict. The unresolved issue is whether the tissue advantage attributed to homografts can survive a weighted analysis of two decades of surgical practice across three centers.